Table 1

Efficacy, tolerability and patient satisfaction of co-enzyme Q10 and amitriptyline in the treatment of cyclic vomiting syndrome

Amitriptyline

Co-enzyme Q10


Pediatric Onset1 <18 y

Adult Onset ≥18 y

All Subjects

Pediatric Onset1 <18 y

Adult Onset ≥18 y

All Subjects


Episode Frequency2

62/113

26/49

88/162

10/17

1/5

11/22

55%

53%

54%

59%

20%

50%


Episode Duration2

59/112

19/43

78/155

5/16

3/6

8/22

53%

44%

50%

31%

50%

36%


Number of Emesis2

52/110

6/16

70/154

6/16

2/4

8/20

47%

41%

45%

38%

50%

40%


Nausea Severity2

47/111

21/46

68/157

7/18

4/7

11/25

42%

46%

43%

39%

57%

40%


Episode Improvement3

88/123

39/54

127/177

12/18

5/7

17/25

72%

72%

72%

67%

71%

68%


Side Effects Reported

72/139

30/63

102/202

0/20

0/8

0/28

52%

48%

50%

0%

0%

0%


Discontinued Therapy Due to Side Effects

29/137

13/61

42/198

0/20

0/8

0/28

21%

21%

21%

0%

0%

0%


Subject Statement of Risks V. Benefits4

49/94

14/40

63/134

13/16

4/6

17/22

52%

35%

47%

81%

67%

77%


Subjects' Recommendation5

65/103

23/39

88/142

12/19

4/6

16/25

63%

59%

62%

63%

67%

64%


Subject on Therapy at Time of Survey

68/111

30/48

98/159

14/19

6/7

20/26

61%

63%

62%

74%

86%

77%


1The number of adolescent-onset cases was small, so the data were combined with the child-onset data.

2Proportion reporting a 50% reduction in this parameter

3Proportion reporting a 50% reduction in at least one of the above four parameters

4"Do you believe that the improvement you receive of [inset treatment name], if any, justified the side effects that you experienced?" - proportion answering as "yes, strongly" or "yes", as opposed to "sort of equal/not sure", "no" or "no, strongly".

5"Would you recommend [inset treatment name] to a friend or relative with CVS?" -- proportion answering as per 4above.

Boles et al. BMC Neurology 2010 10:10   doi:10.1186/1471-2377-10-10

Open Data